)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Corvus Pharmaceuticals
Corvus Pharmaceuticals (CRVS) investor relations material
Corvus Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Soquelitinib development spans PTCL, atopic dermatitis, hidradenitis suppurativa, asthma and ALPS, with multiple clinical milestones planned for 2027.
Phase 3 PTCL and Phase 2 SIERRA1 atopic dermatitis trials remained on track; SIERRA1 top-line data are expected in Q3 2027.
No product sales revenue has been generated.
Financial highlights
Q3 2026 R&D expense was $17.8M vs. $8.5M in Q3 2025, mainly reflecting higher soquelitinib trial and personnel costs; Q3 operating expenses were $21.4M vs. $10.6M.
Q3 2026 net loss was $20.3M vs. $10.2M; nine-month net loss was $52.0M vs. $3.0M, with the prior-year period including a $27.1M warrant fair-value gain.
Q3 net loss per share was $0.22 vs. $0.12; nine-month net loss per share was $0.57 vs. $0.04 basic and $0.38 diluted in 2025.
Q3 stock-based compensation was $2.8M vs. $1.2M; nine-month expense was $8.1M vs. $3.8M.
Nine-month operating cash use was $38.0M; investing cash use was $143.3M, including $239.9M of securities purchases and $102.3M of maturities.
Outlook and guidance
$202.9M in cash, cash equivalents and marketable securities at September 30, 2026, is expected to fund planned operations into Q2 2028.
PTCL event-driven futility analysis is expected in Q1 2027; trial readout is anticipated in late 2027/early 2028.
SIERRA1 top-line data are expected in Q3 2027; a Phase 3 start in 2028 is possible if results support advancement.
HS Phase 1b results are expected in 1H 2027; soquelitinib Phase 2 asthma trial initiation is planned for Q1 2027, enrolling T2 and non-T2 patients.
Angel Pharmaceuticals’ China atopic dermatitis cohort 1 results are expected in Q1 2027; its Phase 2 asthma trial is anticipated to start in Q2 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Corvus Pharmaceuticals
- Oral ITK inhibitor soquelitinib targets multiple immune diseases with pivotal data expected by 2027.CRVS
12th Annual Cantor Fitzgerald Global Healthcare Conference - Soquelitinib shows robust efficacy and safety in AD, supporting broad immune disease potential.CRVSCorporate presentation
- Q2 2026 net loss rose to $18M as R&D spending increased; cash runway extends into Q2 2028.CRVSQ2 2026
- Lead asset soquelitinib advances in oncology and immunology with strong IP and cash runway.CRVSGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Durable efficacy and safety demonstrated in immune diseases, with broad clinical expansion underway.CRVSJefferies Global Healthcare Conference 2026
- Soquelitinib achieved durable efficacy, safety, and immune rebalancing in atopic dermatitis.CRVSStudy update
- Strong efficacy, safety, and immune modulation support Phase II trials for soquelitinib in atopic dermatitis.CRVSStudy result
- Soquelitinib showed robust efficacy and safety, with $31.3M raised to fund operations into late 2026.CRVSQ1 2025
- Soquelitinib advances with strong clinical data and a $52M cash runway into Q1 2026.CRVSQ4 2024
Next Corvus Pharmaceuticals earnings date
Q4 202616 Mar, 2027
Corvus Pharmaceuticals
Next Corvus Pharmaceuticals earnings date
Q4 202616 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing immune-oncology therapies for the treatment of cancer and immune-related diseases. The company’s pipeline includes drug candidates that target key immune pathways to enhance the body’s immune response against cancer cells. The company is headquartered in Burlingame, California, and its shares are listed on the NASDAQ.